Trials / Completed
CompletedNCT00557232
Intraocular Bevacizumab (Avastin) for Rubeosis Iridis
The RAVE (Rubeosis Anit-VEgf) Trial, Utilizes Monthly Intravitreal Bevazizumab (Avastin) Injections for 12 Months to See if Total VEGF Blockade Will Prevent Neovascular Glaucoma and Eliminate the Need for Panretinal Photocoagulation in Patients With Ischemic Central Retinal Vein Occlusion
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Instituto de Olhos de Goiania · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
Bevacizumab (Avastin®, Roche, Rio de Janeiro, Brazil) is an anti-VEGF recombinant humanized monoclonal IgG1 antibody used to treat colorectal cancers. Bevacizumab may have a role in treating ocular disorders involving fibrovascular proliferation. To determine whether intraocular bevacizumab decreases rubeosis iridis in patients with neovascular glaucoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | bevacizumab | 1.25mg/month |
Timeline
- Start date
- 2006-11-01
- Primary completion
- 2011-10-01
- Completion
- 2011-11-01
- First posted
- 2007-11-12
- Last updated
- 2011-11-29
Source: ClinicalTrials.gov record NCT00557232. Inclusion in this directory is not an endorsement.